Search

Wstep: Osoby z zespolem metabolicznej otylości z prawidlową masa ciala (MONW), mimo prawidlowego wskaźnika masy ciala (BMI), są narazone na powiklania typowe dla otylości. Moze to wynikac z subklinicznego stanu zapalnego, wynikającego z nadmiernego gromadzenia tkanki tluszczowej brzusznej. Celem pracy byla ocena związku pomiedzy nagromadzeniem tkanki tluszczowej, szczegolnie okolicy brzusznej, a stezeniem wybranych cytokin prozapalnych — interleukiny 6, 18 i bialka C-reaktywnego (CRP), biorących udzial w aterogenezie. Material i metody: Badaniem objeto 342 osoby (218 kobiet, 124 mezczyzn w wieku 20–40 lat, z BMI > 27 kg/m2), mieszkancow Wroclawia. Grupe podzielono ze wzgledu na wartośc wskaźnika insulinooporności (HOMA): 90 osob — grupa MONW ( HOMA < 1.69), 252 osoby — grupa kontrolna. Oceniono parametry antropometryczne, stezenia IL-6, IL-18, CRP, glukozy, insuliny oraz wskaźniki insulinowrazliwości i insulinooporności. Wyniki: Stezenie CRP bylo istotnie wyzsze w grupie kobiet MONW niz kontrolnej (3,26 vs. 1,97, p = 0,03). Stezenia IL-6 i IL-18 nie roznily sie pomiedzy grupami, zarowno u kobiet, jak i u mezczyzn. Dodatnią korelacje zanotowano miedzy stezeniem IL-6 a wskaźnikiem centralizacji tluszczu u kobiet. Stwierdzono dodatnią korelacje miedzy stezeniem CRP a BMI, wskaźnikiem talia– biodra, obwodem talii u obu plci. U kobiet istniala takze dodatnia korelacja miedzy CRP a wskaźnikami HOMA i FIRI i ujemna ze wskaźnikiem QUICKI. Wnioski: Zwiekszone gromadzenie tluszczu okolicy brzusznej u zdrowych, mlodych osob, wiąze sie z podwyzszonym stezeniem CRP. (Endokrynol Pol 2014; 65 (6): 449–455)

Five to ten percent of women of reproductive age suffer from polycystic ovary syndrome (PCOS). Leptin, NPY, galanin, cholecystokinin (CCK) are involved in the regulation of eating behavior. PPARγ are receptors that are probably involved in hyperandrogenism. This study was designed to assess associations between the Pro12Ala PPARγ2 gene polymorphism and satiety factors in PCOS. Fifty-four PCOS women and 51 healthy women were studied. Leptin, NPY, galanin, CCK levels, and genetic studies to detect Pro12Ala PPARγ2 gene polymorphism were assessed. The leptin levels in the PCOS women carrying Pro12Ala genotype were higher than in those with Pro12Pro and Ala12Ala. The PCOS women had higher leptin and NPY levels and lower galanin levels. Obese PCOS patients had lower CCK levels. Conclusions: In the PCOS women, a single Ala allele may have a protective role as far as hyperleptinemia is concerned. The PCOS women may reveal a disrupted central leptin/NPY feedback loop with some shifts in food intake.

Wstep: Osoby z zespolem metabolicznej otylości z prawidlową masa ciala (MONW), mimo prawidlowego wskaźnika masy ciala (BMI), są narazone na powiklania typowe dla otylości. Moze to wynikac z subklinicznego stanu zapalnego, wynikającego z nadmiernego gromadzenia tkanki tluszczowej brzusznej. Celem pracy byla ocena związku pomiedzy nagromadzeniem tkanki tluszczowej, szczegolnie okolicy brzusznej, a stezeniem wybranych cytokin prozapalnych — interleukiny 6, 18 i bialka C-reaktywnego (CRP), biorących udzial w aterogenezie. Material i metody: Badaniem objeto 342 osoby (218 kobiet, 124 mezczyzn w wieku 20–40 lat, z BMI > 27 kg/m2), mieszkancow Wroclawia. Grupe podzielono ze wzgledu na wartośc wskaźnika insulinooporności (HOMA): 90 osob — grupa MONW ( HOMA < 1.69), 252 osoby — grupa kontrolna. Oceniono parametry antropometryczne, stezenia IL-6, IL-18, CRP, glukozy, insuliny oraz wskaźniki insulinowrazliwości i insulinooporności. Wyniki: Stezenie CRP bylo istotnie wyzsze w grupie kobiet MONW niz kontrolnej (3,26 vs. 1,97, p = 0,03). Stezenia IL-6 i IL-18 nie roznily sie pomiedzy grupami, zarowno u kobiet, jak i u mezczyzn. Dodatnią korelacje zanotowano miedzy stezeniem IL-6 a wskaźnikiem centralizacji tluszczu u kobiet. Stwierdzono dodatnią korelacje miedzy stezeniem CRP a BMI, wskaźnikiem talia– biodra, obwodem talii u obu plci. U kobiet istniala takze dodatnia korelacja miedzy CRP a wskaźnikami HOMA i FIRI i ujemna ze wskaźnikiem QUICKI. Wnioski: Zwiekszone gromadzenie tluszczu okolicy brzusznej u zdrowych, mlodych osob, wiąze sie z podwyzszonym stezeniem CRP. (Endokrynol Pol 2014; 65 (6): 449–455)

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. The psychiatric disorders accompanying the clinical symptoms and hormonal abnormalities are important, but underestimated, aspects in PCOS. Obesity, hirsutism, acne, menstrual disturbances and infertility play important roles in lowering the quality of life in women with PCOS. Depression and anxiety are more often observed in patients with PCOS than in healthy women. Some authors consider that there is a relationship between valproic acid treatment of bipolar disease and PCOS. There have been reports that in women with PCOS anorexia nervosa, bulimia nervosa and other unspecified eating disorders are found more often than in the general population.

Epilepsy is one of the most common neurologic disorders. The epileptic seizures as well as antiepileptic drugs may disturb the reproductive system function. Polycystic ovary syndrome occurs more commonly in women with epilepsy either treated or not with valproic acid. This article discusses the current knowledge about the relationships between epilepsy and polycystic ovary syndrome.

The pathogenesis of PCOS has not been definitively determined and includes a number of genes linked with steroidogenesis, regulation of gonadotropin secretion, actions of insulin, obesity as well as chronic inflammatory processes. Some authors indicate that PPARgamma play a role in insulin sensitivity and are probably involved in hyperandrogenism in PCOS. The aim of the study was to assess the frequency of the Pro12Ala and Pro115Gln PPARgamma2 gene polymorphisms in women with PCOS.54 PCOS women and 51 healthy women were recruited. Genetic studies to detect Pro12Ala and Pro115Gln PPARgamma2 gene polymorphism were performed.In the whole studied group the Pro115Gln polymorphism of the PPARgamma2 gene was not found. The frequency of the Pro12Ala polymorphism was estimated at 26.47% in the controls and at 23.15% in the PCOS patients. Women from the control and PCOS groups with BMIor = 30 had statistically higher occurrence of the Ala allele than women with BMI30 (38.80% versus 12.50% and 38.23% versus 18.75%).The frequency of the Pro12Ala polymorphism observed in the sample of women from the Lower Silesian population was significantly higher than in the majority of European populations.

A body of evidence points to a familial aggregation of hormonal abnormalities in first-degree relatives of women with polycystic ovary syndrome (PCOS). The aim of this study was to determine whether siblings of women with PCOS had evidence of hormonal abnormalities typical of PCOS.Eighty-six siblings of women with PCOS (44 sisters, 42 brothers) were recruited. Two control groups consisted of 70 healthy women and 30 healthy men. Anthropometric, hormonal (testosterone, androstenedione, DHEA-S, LH, FSH) parameters and SHBG were assessed in all subjects.Mean testosterone and DHEA-S levels were higher in sisters of women with PCOS than in the control women. In eight of the 44 (18.2%) sisters, a diagnosis of PCOS was made. Mean testosterone and androstenedione levels, and free androgen index (FAI) were significantly higher in sisters with PCOS compared to the sisters without PCOS. Brothers of women with PCOS had higher DHEA-S level than the control men. Eleven of the 42 (26.2%) brothers had alopecia occurring before the age of 30. Prematurely balding brothers did not differ from the non-balding brothers in hormonal parameters.Siblings of women with PCOS are predisposed to hormonal abnormalities typical of PCOS. The symptom of premature balding under the age of 30 in brothers of women with PCOS should not be considered as a male PCOS equivalent.

Polycystic ovary syndrome (PCOS) is an endocrine disorder with a complex pathogenesis in which hormonal disturbances, metabolic disorders and chronic inflammation have been considered. Relationships among the paraoxonase 1 (PON1) gene, hyperandrogenism and insulin resistance in women with PCOS have been reported.The aim of this study was to evaluate patients with PCOS for the existence of chronic inflammation and to assess the relationship between PON1 polymorphism and hormonal, metabolic and inflammatory parameters in these women.One hundred thirty women with PCOS and 70 healthy women were studied. Anthropometric, hormonal (total testosterone, androstenedione, DHEA-S, LH, FSH), metabolic (fasting glucose and insulin, oral glucose tolerance test, insulin sensitivity and resistance indices, lipids) and inflammatory parameters (hsCRP, fibrinogen, WBC) were assessed and analysis of PON1 Leu55Met polymorphism was carried out in all subjects.WBC, fibrinogen and hsCRP levels did not differ significantly between the PCOS and control groups. The genotype frequencies of the Leu55Met PON1 polymorphism were similar in both groups. There were no relationships between PON1 genotypes and metabolic parameters.As chronic low-grade inflammation was not observed in the women with PCOS, there is no direct link between inflammation and PCOS markers per se. None of the variants of the Leu55Met PON1 polymorphism was associated with more frequent occurrence of PCOS or metabolic disorders, including insulin resistance.

Objective: The aim of this study was to determine whether genetic variation at the cannabinoid receptor-1 (CNR1) locus could have an effect on adiposity, fat distribution and obesity-related metabolic disorders in Polish postmenopausal women.Design and Subjects: The A3813G, G1422A and A4895G single nucleotide polymorphisms of CNR1 were genotyped in 348 randomly selected postmenopausal women aged 50-60 years recruited from the Wroclaw city population. Measurements: CNR1 genotypes, anthropometric measures (BMI, WC, body fat distribution by DEXA) and metabolic parameters (glucose, lipid profile, insulin FIRI) were determined. Results: The 3813G allele was not significantly associated with higher body mass, BMI, WC, total fat, or fat percentage, but was associated with higher android fat deposit (2971.78 &177; 1655.08 &177; 2472.64 &177; 1300.53, p = 0.007) and percentage of android fat (37.59 &177; 8.45 vs. 35.66 &177; 7.63, p = 0.062). The 1422A allele was associated with higher total fat (31587.72 &177; 9161.28 g vs. 26078.26 &177; 7552.14 g, p = 0.019), fat percentage (40.51 &177; 5.66% vs. 37.51 &177; 4.99%, p = 0.052), and percentage of android fat (40.86 &177; 9.73% vs. 36.09 &177; 7.70%, p = 0.047). No associations were observed for the A4895G variant. Conclusions: There is an association of variants of CNR1 with obesity-related phenotypes in Polish postmenopausal women. As CB1 is a drug target for obesity, pharmacogenetic receptor gene analysis of obesity treatment by endocannabinoid blockade may be of interest to identify the best responders.

Homozygosity for interleukin-6 (IL-6) 174G_C promoter polymorphism has recently been associated with indices of metabolic syndrome; however, this problem has not been investigated in non-obese subjects. The aim of this study was to explore the relation between abdominal fat distribution and some inflammatory risk factors of atheromatosis and IL-6 174G_C gene polymorphism in non-obese healthy subjects.Relationships were investigated between anthropometric variables, i.e. weight, height, BMI, waist circumference (WC), waist-to-hip ratio (WHR), body fat distribution (DXA), serum CRP and IL-6, insulin sensitivity/resistance indices, and IL-6 174G_C gene polymorphism, in healthy non-obese Polish subjects: 232 women (age 31.4 +/- 5.5 years) and 199 men (age 30.3 +/- 6.0 years).The genetic study revealed that the CC genotype was observed in 15.56% of subjects, the CG genotype in 52.74%, and the GG genotype in 31.7%. IL-6 and CRP concentration did not differ among the genotypes. There were also no differences regarding BMI and WHR. The only differences among genotypes, observed only in men, were those concerning total fat (CC had higher fat content than CG and GG); the difference being statistically significant between CC and GG (p0.05), and gynoidal fat deposit (CC had higher gynoidal fat deposit than CG and GG); the difference being statistically significant between CC and GG (p0.025) and between CC and CG (p0.05). Biochemical parameters and insulin sensitivity did not differ among the genotypes.These data show that IL-6 174G_C polymorphism is not associated with features describing metabolic syndrome in nonobese healthy subjects.

Dehydroepiandrosterone (DHEA) is postulated to have antiatherogenic properties, but the possible mechanism of this action is unclear. The aim of this study was to determine the influence of endogenous DHEA-S on the levels of some factors playing significant roles in atherogenesis.In a group of 40 premenopausal women, relationships between endogenous DHEA-S and serum lipids and the apolipoproteins A1 (apoA1) and B (apoB), serum lipid peroxide (LPO), and total antioxidant system (TAS) concentrations as markers of the serum antioxidant-prooxidant balance were measured as well as clinical and biochemical parameters playing roles in atheromatosis such as the type of obesity and the serum glucose, insulin, insulin-like growth factor (IGF-1) and homocysteine (HCY) concentrations.Statistical analysis revealed significant correlation (p0.05) between serum DHEA-S level and the serum concentrations of: HDL(2)-C (r=0.53), HDL(2)-C/HDL(3)-C (r=0.58), TG (r=0.35), IGF-1 (r=0.39), and HCY (r=-0.44). There was no statistically significant correlation between DHEA-S level and other biochemical and clinical parameters (age, BMI, WHR) found in this study.Despite unfavorable correlation between DHEA-S and TG concentration, the results of this study indicate a potential antiatherogenic action of DHEA which may occur through various mechanisms: by increasing HDL(2)-C and the HDL(2)-C/HDL(3)-C ratio, which has an atheroprotective effect, by elevating the serum IGF-1 concentration, or by decreasing the HCY level. These preliminary results, however, require further investigation.